NewsHealth / September 17, 2018

Teen First In Indiana To Receive New Cancer Treatment

CAR T cell therapy is a type of immunotherapy where a patient’s T cells are taken from their body and re-engineered to fight their cancer.CAR T cell therapy, Riley Children's Health, leukemia2018-09-17T00:00:00-04:00
Article origination IPBS-RJC
Teen First In Indiana To Receive New Cancer Treatment

Kylee Sweat is Riley Hospital’s first ever CAR T patient and the first pediatric patient to start treatment in Indiana.

Photo courtesy of IU Riley Hospital

An Indiana teenager is the first in the state to receive a new type of cancer treatment for leukemia. CAR T cell therapy was just approved by the FDA last year. 

The treatment is a type of immunotherapy where a patient’s T cells are taken from their body and re-engineered to fight their cancer.  The therapy has been approved for use against leukemia and lymphoma.  

Eighteen-year-old Kylee Sweat relapsed from acute lymphoblastic leukemia or ALL, three times. IU Riley Hospital Dr. Jodi Skiles says in trials the new treatment is effective in more than 80 percent of pediatric ALL cases. 

"Which is unheard of when you are talking about dealing with patients with multiple relapse disease that didn’t respond to standard chemo upfront," says Skiles. 

CAR T cell therapy has fewer side effects and less long-term toxicity.  Kylee’s T cells have been sent to a drug company that will re-engineer them. 

Skiles says CAR T is known as the “living drug.” 

"The really cool thing is that when the cells are re-infused into the patient, the goal, is that not only would those cells attack existing leukemia cells but those cells would also receive a message from the patient’s body to expand and multiply," says Skiles. 

The cells will be transferred back into her body in the coming weeks.  

 

 

Related News

Indiana Unversity Crew Follows NFL's Lead In Implementing Field Safety Practices
Giving Birth In Indiana Can Be Dangerous. It's Worse If You're Black
Riley Hospital For Children Sets $175M Fundraising Goal